Cyclerion Therapeutics (NASDAQ:CYCN) Trading 7.2% Higher – Still a Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shares traded up 7.2% during trading on Thursday . The company traded as high as $1.99 and last traded at $1.93. 878,164 shares were traded during trading, a decline of 80% from the average session volume of 4,346,326 shares. The stock had previously closed at $1.80.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cyclerion Therapeutics has a consensus rating of “Sell”.

Cyclerion Therapeutics Stock Down 14.5%

The company’s 50-day moving average is $1.53 and its two-hundred day moving average is $2.24. The company has a market cap of $6.48 million, a P/E ratio of -2.20 and a beta of 0.96.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.30) EPS for the quarter. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The company had revenue of $0.88 million during the quarter.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.